Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Zimbabwe has been steadily growing in recent years, driven by a combination of factors such as increasing prevalence of rheumatoid arthritis and rising healthcare expenditure.
Customer preferences: Patients in Zimbabwe suffering from rheumatoid arthritis prefer anti-rheumatic drugs that are both effective and affordable. As a result, the demand for generic drugs has been on the rise in the country. Patients also prefer drugs that have minimal side effects and are easy to administer.
Trends in the market: The Anti-Rheumatic Drugs market in Zimbabwe has been witnessing a shift towards biologic drugs. Biologic drugs are more effective in treating rheumatoid arthritis than traditional disease-modifying anti-rheumatic drugs (DMARDs). However, biologic drugs are more expensive than DMARDs and are not easily accessible to the majority of the population in Zimbabwe. This has led to a growing disparity in the treatment of rheumatoid arthritis between the rich and the poor.
Local special circumstances: The healthcare system in Zimbabwe has been facing significant challenges in recent years, including a shortage of medical personnel, inadequate infrastructure, and limited funding. These challenges have impacted the availability and accessibility of anti-rheumatic drugs in the country. The majority of the population in Zimbabwe relies on public healthcare facilities, which are often under-resourced and unable to provide adequate treatment for rheumatoid arthritis.
Underlying macroeconomic factors: Zimbabwe's economy has been struggling in recent years, with high inflation rates and a shortage of foreign currency. This has led to a decline in the value of the Zimbabwean dollar and a rise in the prices of imported goods, including pharmaceuticals. The government has been implementing various measures to address the economic challenges, including currency reforms and austerity measures. However, these measures have had limited success in stabilizing the economy and improving access to healthcare services.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
